A Delaware federal judge has dismissed an infringement lawsuit from Bristol-Myers Squibb and Pfizer seeking to block a generic version of their patented blood thinner drug Eliquis, finding that venue in the First State was improper after the U.S. Supreme Court’s landmark decision in TC Heartland.

The 12-page ruling, from U.S. District Chief Judge Leonard P. Stark of the District of Delaware, followed more than eight months of venue discovery, and rejected an attempt by Bristol-Myers Squibb to attribute the Delaware residency of a Mylan Pharmaceuticals subsidiary to the parent company, which is incorporated in West Virginia.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]